This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Initial Findings Leading to Modifications of Its Research Protocol

The Coronary Drug Project Research Group

JAMA. 1970;214(7):1303-1313.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Physicians face a difficult dilemma concerning pharmacologic therapy for hyperlipidemia in patients with a history of clinical coronary heart disease (CHD). They know that susceptibility to first episodes of premature CHD is directly related to serum levels of cholesterol, and low-density and very-low-density lipoproteins.¹ They are also aware that elevated serum lipids-lipoproteins frequently can be reduced long-term by available drugs. However, they lack the answers to key questions about these pharmaceutical agents: Do they prevent recurrent episodes of CHD and prolong life? What is their mechanism of action? Are they reasonably safe, in long-term usage?

The paucity of scientific data on these critical questions is especially troublesome in view of other problems: Treatment of coronary disease by control hyperlipidemia makes sense only as years-long therapy— and questions about drug toxicity are especially gnawing under this circumstance. Furthermore, almost all the data proving the association between hyperlipidemia and risk of . . . [Full Text PDF of this Article]

Footnotes
For a complete list of the key bodies of the Coronary Drug Project and senior staff members see page 1312.

Reprint requests to Room LL139, Chicago Civic Center, Chicago 60602 (Jeremiah Stamler, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?